soul trial oral semaglutide cardiovascular outcomes results 2025 2024 nejm 💥Soul study group recently shared soul semaglutide Oral and Cardiovascular

DPP4 inhibitors were introduced around the same time as the GLP1 receptor agonists, and have typically been used as second line agents

Real-world outcomes: According to a 72-week phase 3b trial, adults with obesity (but without diabetes) treated with tirzepatide were significantly more likely to lose at least 10% or 15% of their body weight than those treated with semaglutide

Mitochondrial protective and anti-apoptotic effects of Rhodiola crenulata extract on hippocampal neurons in a rat model of Alzheimer's disease

Supports the phases of detoxification and toxin removal from the body

Numerous studies have reported that patients with mood and anxiety-related disorders are characterized by increased circulating inflammatory cytokines, including interleukin (IL)-1, IL-6, tumor necrosis factor (TNF), their soluble receptors, and acute phase reactants such as C-reactive protein (CRP) (Sluzewska, 1999

: